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ABSTRACT  
After intense scientific exploration and more than a decade of failed trials, Alzheimer’s 
disease (AD) remains a fatal global epidemic. A traditional research and drug development 
paradigm continues to target heterogeneous late-stage clinically phenotyped patients with 
single “magic bullet” drugs. 
Here, we propose that it is time for a paradigm shift towards the implementation of 
precision medicine (PM) for enhanced risk screening, detection, treatment, and prevention of 
AD. The overarching structure of how PM for AD can be achieved will be provided through 
the convergence of breakthrough technological advances, including big data science, systems 
biology, genomic sequencing, blood-based biomarkers, integrated disease modeling and P4 
medicine. It is hypothesized that deconstructing AD into multiple genetic and biological 
subsets existing within this heterogeneous target population will provide an effective PM 
strategy for treating individual patients with the specific agent(s) that are likely to work best 
based on the specific individual biological makeup.  
The Alzheimer’s Precision Medicine Initiative (APMI) is an international collaboration of 
leading interdisciplinary clinicians and scientists devoted towards the implementation of PM 
in Neurology, Psychiatry and Neuroscience. It is hypothesized that successful realization of 
PM in AD and other neurodegenerative diseases will result in breakthrough therapies, such as 
in oncology, with optimized safety profiles, better responder rates and treatment responses, 
particularly through biomarker guided early preclinical disease stage clinical trials.  
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The technology industry has entered the field of medicine and boldly aims to eliminate 
disease itself. It may well succeed in a focused global interdisciplinary effort because of a 
convergence of exponentially advancing technologies, including big and deep data science, 
computing, artificial intelligence, sensors, and genomic sequencing. Sequencing of the human 
genome, first completed and published in Nature in 20011 took years for completion at a cost 
of about $3 billion. Today, this is possible in less than a day for about $1,000, with costs 
falling so fast that, by 2022, genome sequencing may be cheaper than a blood test. Now that it 
has been mapped into bits that computers can process, the genome is transforming into an 
information technology. With increasingly large sample sizes and tools such as IBM’s 
artificial intelligence system – Watson – scientists are gaining a better understanding of how 
genes affect health and disease; how food, physical and cognitive exercise, and medicines we 
take affect the complex interplay between our genes and environment.  
We are going to see more medical advances in the next decade than happened in the past 
century. Within the coming years, our genome, epigenome, transcriptome, proteome, 
metabolome, microbiome, interactome, brain network connectome, motor and sensory 
systems, cognition, behavior, lifestyle, and environment will all be mapped, stored, analyzed, 
integrated, and individualized. Precise and prescriptive-medicine systems supported by 
artificial intelligence will help us feel better, be healthier and live longer. 
On January 20 2015, U.S. President Obama outlined the great opportunities for Medicine 
through Precision Medicine (PM) in his State of the Union Address and announced a national 
PM Initiative (PMI) on January 30 (https://www.whitehouse.gov/precision-medicine), flanked 
by the publication of the PMI Cohort Program (PMI-CP) by Francis Collins and Harold 
Varmus in the New England Journal of Medicine on that day2. Since then, the PMI-CP is 
establishing an infrastructure and organization to coordinate and enroll the large national 
research cohort of one million participants in 2016, supported by a $215 million in federal 
support. The PMI-CP targets oncology challenges as a first priority but is also expected to 
expand and transfertilize to other relevant disease areas.  
After more than a decade of failed therapy trials and one of the lowest success rates in drug 
development in medicine, the time has come to launch an international Alzheimer PMI 
(APMI) and link it with the U.S. PMI and other related global initiatives. The establishment 
of a PM paradigm for Alzheimer’s disease (AD), an exponentially growing complex 
polygenic brain disease, requires the incorporation of an array of converging breakthrough 
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technological developments and methods. Systems theory allows for the conceptualization of 
novel and original models to elucidate all systems levels (assessed by systems biology [SB] 
and systems neurophysiology) and different data types in space and time of the complex, non-
linear, dynamic, and chronically progressive nature of the genetically, biologically, 
pathologically, and clinically heterogeneous construct of “AD”3,4, a historical term defined by 
the clinical description of first patients and related first brain histopathological observations5. 
For more than 100 years, Alois Alzheimer’s pioneering AD syndrome was the target of 
scientific exploration. A major step forward was the discovery of single gene mutations on 
chromosomes 21, 14, and 1 resulting in an overproduction of the amyloid beta (Aβ) peptide6
and causing a progressive linear mechanistic neurodegenerative disease leading to familial 
early onset (30-60 years) AD dementia (EOAD) in very small subsets of individuals (<5%). 
From this mutation model, transgenic animals and the majority of AD anti-amyloid drug 
development programs were generated7,8. To date, a major barrier towards a next evolutionary 
step to the PM paradigm for AD is the prevailing “implicit” assumption that the cellular, 
molecular pathophysiological mechanisms and the biological endophenotype of EOAD can be 
perceived as the original linear mono-mechanistic amyloid cascade model9 and extrapolated 
to the pathophysiology of the complex polygenic sporadic late-onset AD (LOAD), 
representing the vast majority of all affected AD patients3. To date, the AlzGene database 
demonstrates substantial genetic heterogeneity in LOAD patients, 695 genes with 2,975 
polymorphisms, more than 20 genome-wide associated risk variants have been described 
(available at http://www.alzgene.org/). However, in a number of the known over 200 
autosomal dominant mutations leading to EOAD different biomarker profiles and clinical 
phenotypes were demonstrated, therefore being far fromhomogeneous10,11. Moreover, even in 
EOAD, the accumulation of pathological Aβ peptide and tau protein never occurs without 
disruption of other major pathophysiological systems (e.g. inflammation, oxidative stress, 
metabolic alterations), thus again underlining the genetic and biological complexity of the AD 
construct in general3,4. In order to untangle this complexity through deconstruction of AD into 
multiple genetic and biological subsets, advancing biomedical research provides a variety of 
data from patients’ complex and diverse pathophysiology through innovative, converging 
exploratory biomolecular tools and neuroimaging modalities. The resulting heterogeneous, 
multidimensional big and deep data are in the process of being standardized and integrated via 
computational and data science methods in the form of mechanistic disease models, according 
to the integrative disease modeling (IDM) conception (Figure 1)12.  
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In this perspective, we outline key aspects and issues for transformation and 
implementation of an AD PM paradigm to advance both treatment and prevention strategies 
in AD. Notably, this results into an innovative scientific taxonomy, a differentiated working 
language (Table 1) for reality-based medicine, which identifies evidence from real-life 
scenarios.  
This and the theoretical background presented in our recently published perspective 
“PRECISION MEDICINE - The Golden Gate for Detection, Treatment and Prevention of 
Alzheimer’s Disease”13,14 provides the theory and roadmap for a new scientific movement 
framed by the newly established Alzheimer Precision Medicine Initiative (APMI). APMI and 
its planned cohort program (APMI-CP) is an international network of leading interdisciplinary 
clinicians, scientists and researchers devoted towards the transformation of Neurology and 
Psychiatry through the implementation of PM, a reintegration of neuroscience and its clinical 
specialties into the theoretical framework of medicine. It is hypothesized, like in parts of 
oncology already achieved, that successful and consequent implementation of PM for AD and 
other neurodegenerative diseases along the disease spectrum of brain proteinopathies will 
result in breakthrough single and combination therapies, with optimized safety profiles, better 
responder rates and more convincing treatment responses, particularly in early disease stage 
clinical trials, providing substantial benefits to individuals on the way to or patients suffering 
from this devastating disease.  
A PRECISION MEDICINE PARADIGM FOR ALZHEIMER’S DISEASE
The adoption of a PM paradigm for generating innovative strategies to treat, prevent and 
cure complex diseases is not a novel concept. For decades, the oncology field was at loss as to 
how to treat patients inevitably dying from advanced late-stage cancer; however, today, 
mortality and cure rates, at least for some forms of cancer, are far beyond initial expectations.  
On the other hand, after over 100 years of accumulating scientific knowledge, there is no 
therapeutic solution for prevention and cure in AD which remains 100% fatal. Available 
treatments, approved for late potentially irreversible clinical disease stages only, offer 
marginal clinical benefits. It is time for a paradigm shift, with the field of oncology providing 
a previously validated model for successful implementation of a PM model that the 
AD/neurodegeneration field can at least partially adopt13.  
The concept of PM aims at tailoring medical treatment to the individual genetic drivers, 
pathophysiological and clinical characteristics of the disease for each single patient15. In other 
7 
words, it aims at tailoring disease prevention and treatment to the individual’s specific 
biological makeup (customized treatment), which is in sharp contrast to the ongoing “one-
drug-fits-all” approach. Given the highly complex nature of AD, the likelihood of identifying 
a single drug to provide meaningful benefit to every patient is minimal, at best. This is the 
situation in other areas such as oncology and cardiology. A key methodological framework 
required for successfully implementing the PM is the incorporation of the exploratory, 
integrative, and interdisciplinary systems approach of SB, complemented by systems 
neurophysiology3,4.  
SB allows a system level approach to drug discovery − with special reference to drug 
target identification, validation, and screening assay development – that embraces the whole 
complexity of disease pathophysiology. Recent years have witnessed significant success in 
biomarker-guided therapeutic strategies in advanced translational research fields of 
biomedicine – including oncology and cardiovascular medicine. The traditional reductionistic 
categorical nosology of “neurodegenerative diseases” reflects advanced late stages of 
fragmented clinical phenotypes and syndromes with different or overlapping histopathological 
patterns. Although continuous working group efforts to refine categorical diagnostic criteria 
improved the diagnostic reliability and accuracy, particularly after integrating biomarkers as 
part of the criteria16, the validity of current categorical nosological systems for 
neurodegenerative diseases remains limited. A step in the right direction is represented by the 
recent formulation of unbiased agnostic biomarker classification systems for AD and 
neurodegenerative diseases to identify and grade risk in normal elderly people. The goal is to 
identify the full spectrum of the specific biological alterations in elderly individuals at risk 
long before the appearance of first clinical symptoms13. 
We hypothesize that using PM in the fields of Neurology, Psychiatry, and Neuroscience 
will trigger a paradigm shift in the medical practice of brain diseases towards preclinical 
detection and effective early interventions. Prevention strategies can be employed before any 
substantial disease progression has occurred, with a strong focus on individualized care.  
Among the objectives of PM are to introduce new paradigms for early detection, 
classification/differential diagnosis, treatment, and prevention of neurodegenerative diseases 
(better proteinopathies of the brain), based on individual biological differences, as reflected 
by multimodal biological indicators, biomarkers4,17,18. In this regard, evolving evidence of AD 
biomarkers has been obtained during the last 20 years from studies performed in 
neurogenetics/neuroepigenetics19-21, neurochemistry22-24 – the latter having been conducted 
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both on cerebrospinal (CSF)25-27 and blood (plasma/serum)28-32 – as well as in 
structural/functional/metabolic neuroimaging33-35, and neurophysiology36,37. Following the 
oncology model, it is anticipated that innovative biomarker studies, combined with SB, will 
identify specific diagnostic, prognostic, and predictive biomarker signatures in order to tailor 
the therapy to individual patients13. Additionally, biomarker-guided PM removes today’s 
“trial-and-error” strategy to pharmacological interventions, which has significant medical 
consequences for patients and healthcare system38. As stated by the Institute of Medicine 
(IOM) Committee Recommendations for Advancing Appropriate Use of Biomarker Tests 
(companion diagnostics) for Molecularly Targeted Therapies, the ultimately goal of PM is to 
improve both the quality of patient care and clinical outcomes39.  
In summary, the PM conception is in the process of being applied to AD and across a 
rapidly increasing number of other neurodegenerative diseases owing to: (I) the development 
of high-throughput “omic” tools designed for screening biomedical samples and (II) the 
setting-up of large-scale biological datasets. Consequent development, validation, and 
implementation of biomarker-guided interventions built on the SB conceptual framework will 
accelerate the path to PM for AD.   
SYSTEMS THEORY AND SYSTEMS BIOLOGY PARADIGMS  
In order to achieve PM, innovative theoretical concepts and strategies need to be 
embraced. The traditional reductionistic approach in AD research aims to characterize single 
pathophysiological pathways affecting specific components of particular systems in a linear, 
non-dynamic and over-simplified manner. This myopic view has resulted in a limited 
representation of complex pathophysiological processes and their interactions. For instance, 
the prevailing amyloid cascade hypothesis speculates that the Aβ peptide is the cause of AD 
and that, as a result, targeting Aβ should lead to substantial disease modification at advanced 
clinical stages in LOAD. This assumption has been challenged by numerous failures of phase 
III clinical trials aimed at modulating Aβ production40 or increasing clearance from the 
brain41,42. Additionally, as stated previously, in no complex model of LOAD Aβ seems to 
occur in isolation of biological dysfunction related to other systems. An agnostic, hypothesis-
free, unbiased systems theory approach seems better suited to explain the complex and 
heterogeneous origin and time course of the pathophysiological failure underlying different 
forms of AD4. For multifactorial diseases like AD, comprehensive holistic systems-level 
approaches are necessary; this is the case of the SB model, which aims at understanding the 
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genotype-phenotype relationships and the mechanisms at the level of genome/epigenome, 
transcriptome, microRNome, proteome/peptidome, metabolome/lipidome, microbiome, 
lifestyle, and environmental factors participating in complex cellular networks3,4,43. 
Correspondingly, SB is based on: (I) advanced molecular and high-throughput “omics” 
methods disclosing and characterizing biomarkers associated with disease mechanisms and 
(II) computational and integrative network biology tools for assimilating multimodal 
information to comprehensively understand the systems-level dysfunction44. Longitudinal 
investigations using the above mentioned SB-based methodologies can provide a full 
characterization of the complex molecular pathophysiology of both single gene and sporadic 
forms of AD. The working hypothesis is that most if not all AD subforms evolve through 
non-linear dynamic convergence of alterations and/or failures in several “systems”, networks, 
signalling pathways, or pathophysiological processes3. As a result, the specific intervention 
needed for a particular individual would depend on the specific system-level alteration and/or 
dysfunction at a given time point, which may change as a function of time and progression 
with (i.e. the specifically effective treatment for a given patient may vary over time).  
“OMICS”-BASED TECHNOLOGIES FOR BIOMARKER IDENTIFICATION  
PM is biomarker-guided medicine. According to the Food and Drug Administration (FDA) 
& the National Institutes of Health (NIH) Biomarkers, Endpoints, and other Tools (BEST) 
Resource, biomarker categories can be divided into the following categories: (I) 
susceptibility/risk biomarker, (II) diagnostic biomarker, (III) monitoring biomarker, (IV) 
prognostic biomarker, (V) predictive biomarker, (VI) pharmacodynamic/response biomarker, 
and (VII) safety biomarker45. In the AD field, however, such fine grained separation between 
different types of biomarkers is largely absent. For example, it is assumed that amyloid 
positivity is both a diagnostic and predictive biomarker, which may or may not be the case for 
given patients. However, the fine-grained specifications of the exact function of each 
biomarker (or biomarker profile) is required to advance PM in AD45. When combining this 
fine-grained categorization of specific types of biomarkers with the evolution of the “omic” 
technologies currently available under the SB methods, there now exists the foundation for 
building the PM based paradigm for treating and preventing AD across the spectrum of 
disease progression45. In genomics, the development of less expensive and comprehensive 
genome-wide arrays paved the way to the genome-wide association studies (GWAS). 
However, although initial results were promising, numerous GWAS were disappointing due 
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to inadequate sample size, limitation of arrays for certain genetic variations (genetic markers), 
and/or heterogeneity in phenotype46,47 as well as the focus on finding the gene(s) responsible 
for AD rather than looking for subsets of AD cases. Big collaborations, such as the 
International Genomics of Alzheimer’s Project (IGAP), and advanced genomic imputation 
techniques (in silico) generated highly consistent GWAS results48,49, which replicate and 
provide insights to underlying biological pathways. Notably, the introduction of next 
generation sequencing (NGS)-based methods led to significantly improve the genomic 
analyses. Particularly, unbiased whole-genome sequencing (WGS) and whole-exome 
sequencing (WES) support the identification of many genetic variants, including SNPs, single 
nucleotide variants, small insertions/deletions, and structural and genomic variants50,51. 
Besides genomics, high-throughput screening methods led to substantial AD-related 
discoveries in other “omic” areas, especially proteomics52,53 and metabolomics/lipidomics54-56
that may change over time by contrast to the genome.  
The “omics”-based screening of disease states is supposed to result in improved 
personalized, mechanistically-based interventions (therapeutic and/or preventive) by revealing 
precise patterns of biomarkers and molecular signatures underlying the exact molecular 
pathophysiological mechanisms active in specific disease states and in individual patients57. 
Substantial attempts are ongoing to explicate key pathways functions, signalling network 
organization, and organism-level responses via high-throughput biological data (for instance, 
global gene expression, comprehensive proteomic data)58. 
Notably, applying SB to blood-based “omic” technologies to promote the PM paradigm for 
AD will enable two primary advances for improved patient outcomes13,59: (I) generation and 
validation of enhanced multi-stage neurodiagnostic processes and (II) identification of 
targeted therapeutic intervention strategies for specific patients or subgroups of patients59. As 
with the PM paradigm successfully implemented in oncology, a primary key to success is the 
generation of early detection biomarkers identifying patients before significant pathological 
accumulation. As with other frontline detection strategies, blood-based tools detecting 
patients within primary care settings in the earliest stages of disease progress will foster a 
multi-stage diagnostic process for appropriate referrals to CSF and positron emission 
tomography (PET) biomarker methods. Additionally, once such a multi-stage process is 
established, it would provide support to the global AD clinical trials community. The second 
advancement will be the identification of which specific patients are most likely to benefit 
from precise and definite interventions. Applying SB for the analysis of multi-level blood-
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based “omic” data will facilitate the segregation of patient populations into biologically-based 
subgroups that can be further scrutinized for targeted interventions. Using SB methods to 
create diagnostic biomarkers of specific subsets of AD patients will have a tremendous impact 
on the advancement of the PM paradigm in AD59.  
THE PATH FROM “BIG DATA” TO “SMART DATA” 
SB aims at exploring the enormous complexity of biological systems by (I) outlining the 
components of the system, (II) clarifying their interrelations, and (III) defining their spatio-
temporal dynamics needed for executing their biological functions60. According to the 
Workshop “From Systems Biology to Systems Medicine” – organized by the European 
Commission, Directorate of Health – the application of SB-based strategies to medical 
research/practice is referred to as systems medicine. The objective of systems medicine is to 
integrate a variety of massive biomedical data at all levels of the cellular organization by 
employing global, integrative, and dynamic statistical and computational modeling to 
elucidate the pathophysiological mechanisms, diagnosis, prognosis, and therapy of the disease
(https://ec.europa.eu/research/health/large-scale/pdf/systems-medicine-workshop-report-june-
2010_en.pdf). The era of “omics” sciences – describing complex biological systems in an 
integrative, non-reductionistic (holistic) manner – led to the generation of large-scale and 
heterogeneous biomedical data and allowed entering the area of “big data” in Biology and 
Medicine13. Big data is a comprehensive expression referring to the complexity, challenges, 
and new opportunities presented by the combined analysis of data. These data sources include 
the heterogeneous, complex, disorganized, massive, and multidimensional data (from 
molecular/cellular data, to conventional clinical data, to enormous amounts of imaging, 
demographic, and environmental data) extensively produced by academic institutions, clinics, 
and mobile devices60,61. These datasets, due to their large sizes and complexities, cannot be 
analyzed using the traditional ways of processing the data. Big data usually display: (I) 
significantly enormous amount of data, (II) elevated speed of data production, and (III) 
heterogeneity of data generated by using different modalities. Such features are typically 
found in several large assortments of data62. In this regard, the Obama Administration 
announced the Big Data Research and Development Initiative 
(https://www.whitehouse.gov/blog/2012/03/29/big-data-big-deal) aimed at targeting 
personalized medicine through the Genomic Information System for Integrated Science 
(GenISIS) program to improve health care for Veterans. Of note, in 2012, the U.S. National 
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Institutes of Health (NIH) launched the Big Data to Knowledge (BD2K) Initiative 
(https://datascience.nih.gov/bd2k), to support the research of innovative methods to speed up 
the integration of big data into biomedical research63. In order be successful, the PMI must 
utilize innovative methods for collecting/managing big data. This is accomplished by 
remarkable progresses in information technology that provided significant reductions in terms 
of costs of data storage, and substantial increases in analytic capabilities, thus enabling the 
collection and examination of exceptionally large datasets in biomedicine. Particularly, the 
development and implementation of electronic health records (EHRs) allow 
gathering/preserving longitudinal health care records and clinical data at limited costs. EHRs 
represent a key source of clinical data to examine biological and environmental contributions 
to a large number of conditions and health outcomes. Additionally, there has been an 
exponential growth in terms of adoption of personal mobile technologies – including phones, 
apps, wearables, in-home devices – as innovative way to collect health information (mobile 
health or “mHealth”) aimed at collecting clinical relevant information in a more ecological 
environment, and improving patient care and advancing research. Data generated from 
increasingly sophisticated software applications can enrich self-reported data on lifestyle and 
environment, thus providing researchers with a well-defined view into these factors 
previously difficult to capture. 
The holistic paradigm of systems medicine utilizes all assortments of biological 
information – DNA/RNA, protein/peptides, metabolites/lipids, other small molecules, cells, 
tissues, organs, individuals, social networks, and external environmental signals – integrating 
them in such a way that predictive and “actionable” models for health and disease are 
generated60. Presently, unparalleled amounts of heterogeneous data are being gathered with 
content in AD, ranging from genetic/epigenetic and molecular “omic” disciplines to clinical 
phenotypes of patients. The production of such big data is expected to radically renovate the 
development of effective therapies for AD, under the condition that such data are converted 
into “actionable” knowledge64. In the AD domain knowledge is defined as “actionable” when 
it can be utilized to actively support drug discovery & development programs for therapeutic 
interventions, to define potential groups of responders to specific targets, and to validate 
clinical data that can indicate the presence of substantial changes during the advancement of 
the disease65. The integration of large clinical datasets is considered as a potentially powerful 
approach to accelerate medical discovery based on recent results of world-wide studies of 
disease progression and large-scale genomics efforts66. Innovative analytical methods have 
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been developed both in the field of bioinformatics67,68 and in pharmacology69. According to 
Geerts and colleagues (2016), the attempts of gathering large-scale data, such as the 
Alzheimer’s Disease Neuroimaging Initiative (ADNI) consortium (http://adni.loni.usc.edu/) 
are assumed to yield maximal impact if they are combined with advanced predictive modeling 
approaches where large neurobiological domain expertise is formally integrated. Such an 
approach is referred to as converting big data into “smart data” with the aim of producing 
“actionable” knowledge. This strategy is envisioned to emphasize the link between the 
domain of data-information and that of “actionable” knowledge, i.e. the notion of “smart 
data”64. The creation of “actionable” knowledge is intended to support the development of 
novel paradigms that will be used for therapeutic purposes. In this regard, the Brain Health 
Modeling Initiative (BHMI) has been recently introduced64 with the objective of accelerating 
the development and validation of biomarkers and therapeutic agents by highlighting the role 
of integrative analytic tools and mechanism-based computational methods. These will 
improve the mining of complex big datasets to obtain an increasingly accurate and 
“actionable” understanding of the disease. This initiative is expected to result in the 
development of more successful treatments or an improved efficient screening of patients 
with AD-specific pathophysiology or an enhanced match between biomarkers and therapeutic 
targets64,70. This will fully support the application of the PM paradigm2 involving matching 
patients to a therapy focused on the pathophysiological features of their disease. In summary, 
the “big data” advancements provide a platform upon which the “omics” data can be 
understood from a SB standpoint for the generation of a PM paradigm in AD (Figure 1).  
THE PATH TO INTEGRATIVE DISEASE MODELING AND P4 MEDICINE 
INCLUDING ONTOLOGY AND TAXONOMY ISSUES 
Neurodegenerative diseases or protein misfolding disorders/proteinopathies of the brain 
leading to neurodegeneration, present a large continuous spectrum of phenotypical subtypes 
and substantial complexity in terms of genetics, pathophysiology and molecular and 
topographical progression patterns. This is partly due to the high complexity of the 
evolutionary driven human brain organization, lack of direct access to brain tissue in living 
patients, and large heterogeneity and overlapping clinical signs, symptoms and syndromes. As 
a result, biomedical research in the field of neurodegenerative diseases including AD is 
presently focused on indirectly obtaining data from the brains of patients using a variety of 
clinical, molecular neurophysiological and neuroimaging assessments and technologies. 
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However, a major challenge is that these data are vast, heterogeneous, and scattered. Thus, a 
multidimensional data space has been created over time that needs standardization, 
management, integration, and analysis. Computational approaches have been recently 
developed to facilitate these processes and present the integrated data in the form of 
mechanistic disease models, i.e. IDM. The IDM methodology aims at linking molecular, 
neurophysiological and neuroimaging data across multiple physiological levels to clinical 
readouts and phenotypic observations in such a way that further analytical actions, including 
mode-of-action simulation and outcome prediction, can be performed on integrative models.
The first and the most important step towards integrative modeling of the multidimensional 
data space of neurodegenerative diseases is represented by the standardization and 
representation of the knowledge domain of brain diseases. 
Ontologies provide a secure and stable tool to achieve this goal. An ontology is a formal 
naming and definition of the types, properties, and interrelationships of the entities that really 
or fundamentally exist for a particular domain of discourse. It is thus a practical application of 
philosophical ontology, with a taxonomy. The ontology compartmentalizes the variables 
needed for some set of computations and establishes the relationships between them. The 
fields of artificial intelligence, the Semantic Web, systems engineering, software engineering, 
biomedical informatics, library science, enterprise bookmarking, and information architecture 
all create ontologies to limit complexity and to organize information. The ontology can then 
be applied to problem solving. The most well-known ontology in the biomedical community 
is Gene Ontology (GO) (http://geneontology.org/), which organizes expert knowledge about 
genes, their function, cellular location, and biological processes71. However, GO is devoid of 
disease concept, meaning that gene function and processes have been annotated for 
physiological conditions. Recently, several attempts have been undertaken to formalize the 
knowledge domain of neurodegenerative diseases for the use in integrative disease models. 
Notably, Malhotra and colleagues (2014) pioneered the development of the AD Ontology72
and Younesi and colleagues (2015) published the first ontology draft for Parkinson’s 
Disease73. Other ontologies have been consequently created74,75. Interestingly, Iyappan and 
colleagues (2016) defined a pathway terminology system representing a comprehensive set of 
signalling pathways and biological events to mine the knowledge domain of AD and visualize 
the perturbed pathways on top of their corresponding anatomical locations in human brain76. 
Using these domain-specific ontologies and vocabularies, it is possible to annotate and 
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harmonize both quantitative (e.g. expression metadata) and qualitative (e.g. textual) data. 
Such curated datasets provide the substrate for data integration. 
After standardization and annotation of scattered datasets, these quality datasets should be 
properly managed and handled within specific computational platforms so that they can 
become amenable to modeling and further analysis. One such platform is the AETIONOMY 
knowledgebase, an IMI-funded resource aiming at gathering, organizing, and managing 
knowledge and data on neurodegenerative diseases with focus on AD and Parkinson’s disease 
(available at http://www.aetionomy.eu/en/vision.html). The AETIONOMY platform is based 
on the tranSMART architecture, a knowledge management platform assisting researchers to 
generate data-driven hypotheses (available at http://transmartfoundation.org/). 
The integration of curated datasets within data management platforms requires robust 
modeling methods. Although many algorithms have been introduced to integrate quantitative 
and qualitative data and visualize them in the form of correlational and causal networks, these 
networks are usually not multidimensional and model one or two types of relations between a 
few numbers of biological entities. For instance, the AlzPathway map provides a collection of 
signalling pathways and biological events taught to be involved in the AD pathogenesis77. 
However, these maps lack of other data dimensions such as SNPs, epigenetic regulators, and 
clinical outcomes; moreover, they are not amenable to computational reasoning and dynamic 
simulation. In this regard, Biological Expression Language (BEL) is a modeling language 
addressing these caveats to a large extent. The principles underlying this modeling approach 
include standard representation of triples and their relationships (i.e. subject-relation-object) 
with clear directions for the relations as cause and effect (available at http://openbel.org/). 
Probably, the most important utilization of IDM is prediction of outcome. BEL models 
have been successfully applied to predicting AD pathophysiological mechanisms and 
biomarker identification tasks78. For instance, they can be subjected to reasoning algorithms 
such as Network Perturbation Analysis to predict the network behaviour under disease 
conditions using transcriptomic data79. 
Having said that, disease-specific integrative computational models play a crucial role in 
the IDM paradigm and constitute foundations for “actionable” P4 medicine measures in the 
area of AD and other neurodegenerative diseases (Figure 1). Accordingly, the integrative 
disease models are expected to support decision making for (I) early diagnosis of brain 
disease progression with mechanistic biomarkers (predictive), (II) stratification of individuals 
at high risk of developing neurodegenerative diseases based on mechanistic comorbidities 
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(preventive), (III) tailoring treatment to the right patient population (personalized), and (IV) 
optimizing “actionable” plans for the benefit of patients based on patient-centric information 
in EHRs and patients’ feedback in social media12. 
DATA SCIENCE AND INTEGRATIVE DISEASE MODELING: FROM 
CONCEPTS TO METHODS TO CLINICAL APPLICATION  
“Data science”, a new scientific field at the interface between mathematics, statistics, and 
computer science, had already a deep impact on many aspects of human activities, thanks to 
the automatic prediction of individual behaviour from personal data. Back up by advances in 
artificial intelligence and machine learning, this field is likely to play a pivotal role in the 
emergence of PM.
Large multimodal observational studies are acquired within clinical research with the aim 
to better understand the pathophysiology of diseases and identify potential therapeutic targets. 
In most cases though, such datasets serve to validate a specific set of hypotheses, with the 
common belief that data have a short time lapse before their value expires. The potential value 
of retrospective use of these data with hypothesis-free approaches is currently underestimated. 
However, they represent a huge potential to design effective systems to automatically position 
each patient into a disease progression scale, predict symptoms onset, find pathological sub-
types, monitor disease progression, and predict treatment efficacy for each patient.  
Nevertheless, this potential can only be exploited by the development of specific 
methodologies. In this regard, neurodegenerative diseases, spanning dynamically over 
decades in the life of individuals, represent great theoretical and computational challenges. 
The idea is to design an artificial intelligence system that will synthetize the changes observed 
in the data into one or several integrative digital models of disease progression that, in turn, 
will be used to estimate the current and future state of a certain patient given its past 
observations. Designing such systems requires: (I) building long-term disease progression 
models from collecting short-term observation data, where each patient is examined a 
different number of times, at different time-points; (II) integrating in the model various 
categories of structured data: clinical measurements, biological (blood/CSF) markers, 
structural/functional/metabolic imaging data, and potentially molecular data; (III) temporally 
co-registering the disease trajectories of every patient, which may start at a different age with 
a different pace and pathophysiological pattern; (IV) accounting for inter-individual 
variability in terms of spatio-temporal patterns of disease progression, since each individual 
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shows different anatomical/physiological/functional characteristics and these features will 
change in each patient in a different way; (V) turning descriptive scenarios of disease 
progression into predictive systems.  
The integration of spatio-temporal measurements into a digital model of disease 
progression is often based on the idea of regressing measurements against an estimated time 
to disease onset80,81. However, the goal of automatic diagnosis/staging/prognosis systems is 
estimating such a time to disease onset, which cannot be then a pre-requisite. This difficulty 
led to pragmatic solutions to temporally re-align disease trajectories, especially for set of 
unstructured measurements without spatial organization like whole images82-85. Another 
challenge is not only describing the scenario of events occurring during the disease course, 
but also the variability of such a scenario among different individuals. Mixed-effects models 
seem to be a piece of choice to account for both population and individual effects86, and, 
therefore, pave the way to digital models that may be personalized to individual cases. 
Such mixed-effect models may be used together with the combination of spatial 
normalization and temporal alignment, with re-synchronisation of the individual timeline 
using the concept of “time warps”87,88 or permutation of discrete events89. These ideas led to 
predictive staging systems, where patients are given an estimated stage of disease 
progression89,90.  
The question of how to disentangle variations in measurements and in pace of changes 
from longitudinal observations still remains open. However, recent theoretical developments 
for estimating the statistical distribution of individual trajectories are promising91,92. A 
practical example of what can be done within this framework is illustrated in Figure 2
representing Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-Cog) scores 
of 248 individuals pooled into 4 categories of cognitive functions (i.e. memory, concentration, 
language, and praxis).  
CONCLUDING REMARKS  
The field of medicine is at a tipping point, a transformational stage, with emerging 
paradigm shifts in how we conceptualize medical science and research. Clearly one, if not the 
major breakthrough objective is set out to accomplish PM, facilitated by converging advances 
in theory and technology, such as SB, genomic sequencing, exploratory high-throughput 
analyses, the emergence of blood-based biomarkers, data and computational science, 
integrated disease modeling, EHRs, smart technologies and P4 medicine. Towards this end, 
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the PMI-CP (https://www.whitehouse.gov/precision-medicine and 
https://www.nih.gov/precision-medicine-initiative-cohort-program) – launched in January 
2015 by the U.S. President Obama – is noteworthy. Under this program, over a million U.S. 
citizens are expected to provide their genetic data, biological samples and behavioral data, 
which will be extensively characterized and subsequently linked to EHRs. High-density data 
that will be generated through the application of SB will be invaluable to dissect the 
molecular underpinnings of different common complex diseases, which will lead to the 
development of safe and effective individually-tailored biomarker-guided therapies.  
The fields of Neurology, Psychiatry and Neuroscience have yet to follow these giant 
footsteps and reintegrate into Medicine embracing PM as primary target of concerted efforts. 
The field AD and other neurodegenerative diseases (or brain protein misfolding 
disorders/proteinopathies with neurodegenerative pathology) has a larger economic impact 
than cancer, yet surprisingly an equivalent and appropriate level of funding has by far never 
been granted to the global epidemic of AD93. Learning from the advances in oncology, there 
is no choice than to accelerate the acceptance and implementation of the PM paradigm for 
improved health outcomes, which will have a significant impact on worldwide economic 
outcomes. After more than a decade of clinical trial failures the acceptance of a PM paradigm 
for AD research and drug development is gaining momentum and this is why the time is right 
(in the worst of times with exponentially rising investments into R&D and equally decreasing 
rates of a success in therapy developments) for us to initiate and establish a global initiative, 
the APMI consortium (Figure 1). Consequently, PM in the field of AD and 
neurodegeneration should target genetic risk and the molecular stages of disease, meaning at 
the earliest preclinical asymptomatic stage94, when the disease is potentially reversible, 
tailored to delay, stop – and possibly prevent – the progression to clinical signs and 
symptoms. Both citizens (active participants and no longer study “patients”) and policy-
makers need to become more actively engaged with caregivers, basic scientists, and clinical 
researchers in a common effort to internationalize, centralize and revolutionize the current 
approach to clinical and translational neurological and psychiatric research. Inevitably, this 
requires a radical theoretical and cultural shift from traditional concepts, based on the 
treatment of late stage diseases guided by heterogeneous clinical phenotypes treated by 
hypothesized “one-size fits all - magic bullet therapies”, to the patient centered PM-based 
approach, focused on early screening for risk and detection of biology, with customized 
targeted and biomarker-guided therapies to achieve effective and safe prevention and therapy 
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grounded on the biological characteristics of the individual patient. The vision and objective 
of the APMI is to facilitate a paradigm shift and transformation of research towards PM 
through international interdisciplinary networking and collaboration. 
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FIGURE CAPTIONS 
Figure 1. Translational bench to bedside data flow within the conceptual framework of the 
Alzheimer Precision Medicine Initiative (APMI). 
The IDM Data Sciences lifecycle takes advantage of both data- and knowledge-driven 
approaches so that quantitative (biomolecular, neuroimaging, neurophysiological and clinical 
data) and qualitative (literature data) are first represented in a harmonized, standardized 
format to be prepared for proper management within an integrative computational 
infrastructure. Once these heterogeneous datasets and scales are leveraged, the next step is to 
integrate them using modeling algorithms that allow for further analysis such as predictive 
operations (reasoning, simulation, and visualization). The output should be an “actionable” 
model that predicts the trajectory of individual patient-centric detection or treatment within 
the P4M implementation.  
Abbreviations: APMI cohort or APMI-CP, Alzheimer Precision Medicine Initiative cohort 
or cohort program; IDM, Integrative Disease Modeling; P4M, P4 (Predictive, Preventive, 
Personalized, and Participatory) medicine.  
Figure 2. Digital model of cognitive decline in AD, built from the ADAS-Cog scores 
(pooled into 4 categories of cognitive functions) observed repeatedly in 248 subjects with an 
average of 5 follow-up visits, who progressed from prodromal stage MCI to AD dementia 
during the observation period (data derived from the ADNI). The model consists of an 
average disease progression model showing the typical scenario of cognitive decline from 
prodromal symptomatic (MCI) to syndromal symptomatic (dementia) stages of AD (panel a), 
and a set of parameters showing the variability of this scenario in terms of age at disease onset 
(panel b), pace of cognitive decline (panel c), temporal ordering and relative delay between 
declines of different cognitive functions (panels d e and e) within the studied population. 
28 
Abbreviations: AD, Alzheimer’s disease; ADAS-Cog, Alzheimer’s Disease Assessment 
Scale-cognitive subscale; ADNI, Alzheimer's Disease Neuroimaging Initiative; MCI, mild 
cognitive impairment.  
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Table 1: Evolving lexicon and terminology of Precision Medicine 
Concept Abbreviation Definition
Big Data A repository of large amounts of data sets generated by 
data mining tools. Big Data includes information obtained 
through systems theory- and, knowledge-based approaches 
and clinical records 
Biomarkers BMs A defined characteristic that is measured as an indicator of 
normal biological processes, pathogenic process, or response 
to an exposure or intervention, including therapeutic 
interventions. Molecular, histologic, radiographic, or 
physiological characteristics are types of biomarkers. A 
biomarker is not an assessment of how an individual feels, 
functions or survives. Categories of biomarkers include: 
susceptibility/risk biomarker, diagnostic biomarker, 
monitoring biomarker, prognostic biomarker, predictive 
biomarker, pharmacodynamics/response biomarker and safety 
biomarker45
Data Science Interdisciplinary field about processes and systems to 
extract knowledge from data in different forms, either 
structured or unstructured, which is a continuation of some of 
the data analysis fields including statistics, artificial 
intelligence, machine learning, data mining, and predictive 
analytics
Electronic Health Records EHRs Systematized gathering of population electronically-stored 
health information and clinical data in a digital format. These 
registries can be shared across different health care settings 
through network systems. EHRs eliminate the need to track 
down a patient’s previous paper medical records and assist in 
ensuring that data are accurate and legible
Genomic Medicine Discipline utilizing personal genomic information for 




IDM Multidisciplinary approach to standardize, manage, 
integrate, and interpret multiple sources of structured and 
unstructured quantitative and qualitative data across 
biological scales using computational models that 
assist decision making for translation of patient-specific 
molecular mechanisms into tailored clinical applications
Mobile Health mHealth Smart personal mobile devices (phones, wearables, in-
home devices and Apps) collecting health information aimed 
at improving patient care
Omic Disciplines High-throughput screening tools aimed at fully collecting, 
characterizing and quantifying pools of biological molecules 
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(DNA sequences, transcripts, proteins, metabolites/lipids) that 
translate into the structure, function, and dynamics of an 
organism and/or organisms
Ontology Formal naming and designation of the types, properties, 
and interactions of the entities that really or fundamentally 
exist for a specific domain of discourse
P4 (Predictive, Preventive, 
Personalized, and 
Participatory) Medicine
P4M Translational medicine component of the Precision 
Medicine paradigm. It is a clinical practice model aimed at 
applying knowledge, tools, and strategies of systems 
medicine. It involves generation, mining, and integration of 
enormous amounts of data on individual patients to produce 
predictive and “actionable” models of wellness and disease
Personalized Medicine Component of P4 Medicine aiming at tailoring treatment 
for individual patients in contrast with “one-size fits-all” or 
traditional “magic bullet” drug approach
Precision Medicine PM Translational science paradigm related to both health and 
disease. PM is a biomarker-guided medicine on systems-
levels taking into account methodological advancements and 
discoveries of the comprehensive pathophysiological profiles 
of complex polygenic, multi-factorial neurodegenerative 
diseases (proteinopathies of the brain). It aims at optimizing 
the effectiveness of disease prevention and therapy, by 
considering (customized) an individual’s specific biological 
makeup (e.g. genetic, biochemical, phenotypic, lifestyle, and 
psychosocial characteristics) for targeted interventions 
through P4M implementation 
Systems Biology SB Evolving hypothesis-free, exploratory, holistic (non-
reductionistic), global, integrative, and interdisciplinary 
paradigm using advances in multimodal high-throughput 
technological platforms that enable the examination of 
networks of biological pathways where elevated amounts of 
structurally and functionally different molecules are 
simultaneously explored over time at a system level (i.e., at 
the level of cells, group of cells, tissues, organs, apparatuses, 
or even whole organisms)
Systems Medicine Holistic paradigm applying systems biology-based 
strategies to medical research. It aims at integrating a variety 
of considerable biomedical data at all levels of the cellular 
organization (by employing global, integrative, and 
statistical/mathematical/computational modelling) to explicate 
the pathophysiological mechanisms, prognosis, diagnosis, and 
treatment of diseases
Systems Theory ST Translational research theory of the Precision Medicine 
paradigm. It is an interdisciplinary conceptual framework 
allowing for the conceptualization of novel/original models to 
31 
extract and explicate all systems levels and different 
spatiotemporal data types of complex polygenic diseases
Taxonomy Scientific classification into groups based on shared 
characteristics and natural relationships. Taxonomy adds a 
relation dimension between individual items and is defined as 
a way to group similar items together 
